NYSE: EVMNEvommune Inc Stock
$22.18-1.49 (-6.29%)
Updated Mar 27, 2026
EVMN Price
$22.18
Fair Value Price
N/A
Market Cap
$798.89M
52 Week Low
$13.89
52 Week High
$33.20
P/E
-1.98x
P/B
3.89x
P/S
8.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.00M
Earnings
-$68.87M
Gross Margin
100%
Operating Margin
-529.77%
Profit Margin
-529.8%
Debt to Equity
0.09
Operating Cash Flow
-$76M
Beta
1.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EVMN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EVMN
Ranked#236 of 466
Ranked#236 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $182.69 | A | |
| $30.01 | A | |
| $16.31 | A |
Be the first to know about important EVMN news, forecast changes, insider trades & much more!
EVMN News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVMN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVMN is good value based on its book value relative to its share price (3.89x), compared to the US Biotechnology industry average (4.52x)
P/B vs Industry Valuation
EVMN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EVMN due diligence checks available for Premium users.
Valuation
EVMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.98x
Industry
27.96x
Market
30.7x
EVMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.89x
Industry
4.52x
EVMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$28.3M
Profit Margin
0%
EVMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EVMN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$224.9M
Liabilities
$19.4M
Debt to equity
0.09
EVMN's short-term assets ($153.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVMN's short-term assets ($153.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.7M
Investing
-$122.9M
Financing
$156.8M
EVMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVMN vs Biotech Stocks
Evommune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.